Are Analysts Bearish MacroGenics, Inc. (NASDAQ:MGNX) After Last Week?

Investors sentiment decreased to 0.92 in 2019 Q2. Its down 1.23, from 2.15 in 2019Q1. It fall, as 28 investors sold MacroGenics, Inc. shares while 34 reduced holdings. 12 funds opened positions while 45 raised stakes. 39.29 million shares or 2.04% less from 40.11 million shares in 2019Q1 were reported.
Prelude Mngmt Limited Liability holds 272 shares. Fosun Ltd holds 131,573 shares. Amer Group has 30,308 shares. Cubist Systematic Strategies Ltd Com owns 61,501 shares. Susquehanna Gru Llp has 73,507 shares. 485,000 are owned by Eventide Asset Management Ltd Liability Co. Manufacturers Life Ins Comm The holds 0% or 29,933 shares in its portfolio. Aqr Capital Ltd Com owns 15,870 shares. Millennium Mngmt Limited Liability owns 2.95 million shares for 0.08% of their portfolio. Opus Point Prtn Mngmt Ltd Liability has invested 0.75% in MacroGenics, Inc. (NASDAQ:MGNX). Jpmorgan Chase Communications invested in 26,886 shares. 26,261 are owned by Credit Suisse Ag. 178,400 are held by Axa. Moreover, State Common Retirement Fund has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX). Federated Investors Pa stated it has 0.04% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX).

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 2 analysts covering Macrogenics (NASDAQ:MGNX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Macrogenics has $29 highest and $2500 lowest target. $27’s average target is 137.26% above currents $11.38 stock price. Macrogenics had 3 analyst reports since April 17, 2019 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 1 report. Below is a list of MacroGenics, Inc. (NASDAQ:MGNX) latest ratings and price target changes.

01/08/2019 Broker: Stifel Nicolaus Rating: Buy Old Target: $29.0000 New Target: $25.0000 Maintain
03/05/2019 Broker: Inc. – Common Stock Rating: Wedbush 26.0000
17/04/2019 Broker: Credit Suisse Rating: Outperform New Target: $29 Initiates Coverage On

The stock increased 0.53% or $0.06 during the last trading session, reaching $11.38. About 300,947 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 28.01% since October 12, 2018 and is downtrending. It has underperformed by 28.01% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $556.41 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

More notable recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: which released: “Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against MacroGenics, Inc. – Business Wire” on September 13, 2019, also with their article: “3 Stocks With Big News Coming at ASCO 2019 – Motley Fool” published on May 15, 2019, published: “MacroGenics: Margetuximab’s Potential Makes It Massively Undervalued – Seeking Alpha” on June 10, 2019. More interesting news about MacroGenics, Inc. (NASDAQ:MGNX) were released by: and their article: “MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA – GlobeNewswire” published on January 25, 2019 as well as‘s news article titled: “Sell-siders weight in on ESMO data presentations – Seeking Alpha” with publication date: September 27, 2019.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.